66th ASH Annual Meeting: 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials

Symposia: Health Services and Quality Improvement: Lymphoid Malignancies Oral and Poster Abstracts
Oral

Research, Lymphoid Leukemias, Clinical trials, Hodgkin lymphoma, Acute Myeloid Malignancies, Adult, Clinical Practice (Health Services and Quality), Lymphomas, Non-Hodgkin lymphoma, Bispecific Antibody Therapy, CLL, Clinical Research, Health outcomes research, Plasma Cell Disorders, B Cell lymphoma, Health disparities research, T Cell lymphoma, Chronic Myeloid Malignancies, Diversity, Equity, and Inclusion (DEI), Diseases, Indolent lymphoma, Real-world evidence, Treatment Considerations, Biological therapies, Aggressive lymphoma, Lymphoid Malignancies, Young adult , Survivorship, Myeloid Malignancies, Study Population, Human

San Diego Ballroom AB (Marriott Marquis San Diego Marina)

Moderators:

Xu Ji, PhD, Emory University / Children's Healthcare of Atlanta and Christopher T. Su, MD, MPH, ARRAY(0xe8ca1d4)

Disclosures:

No relevant conflicts of interest to declare.

10:30 AM

781

Barriers to Immune Effector Cell Therapy: Rapid Disease Progression, Concern for Toxicity, and Lack of Appropriate Trials Drive Non-Receipt after Referral at a Large Academic Center

Yannis K. Valtis, MD¹, Kuo-Kai Chin, MD², Meira Yisraeli Salman, MD², Leora Boussi, MD², Briana Cadzin, RN³^*, Carina Mcloughlin⁴^*, Elizabeth Cathcart⁵^*, Paul Davis⁴^*, Chelsea Brooklyn⁴^*, Todd Goldstein⁴^*, Christopher Famulare, MS²^*, Gunjan L. Shah, MD⁶, Moneeza Walji, MD, BSc, MPH⁷, Alexander P. Boardman, MD⁸^*, Roni Shouval, MD, PhD⁹, Eytan M. Stein, MD¹⁰, Sham Mailankody, MD, MBBS¹¹, Maria Lia Palomba, MD⁸, Gilles Salles, MD, PhD¹², Sergio Giralt, MD¹³, Miguel Angel Perales, MD¹ and Jae H. Park, MD¹⁴

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Memorial Sloan Kettering Cancer Center, New York
⁵Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Transplant and Cellular Therapy Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Department of Medicine; Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
¹¹Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹²Lymphoma Service Chief, Memorial Sloan Kettering Cancer Center, New York, NY
¹³Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁴Cell Therapy Service and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

10:45 AM

782

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Scott F Huntington¹, Anthony Masaquel²^*, Esprit Ma²^*, Eric Zuk³^*, Hélène Parisé³^*, Matthew Davis³^*, David Fox²^*, Fadoua El Moustaid²^*, Arliene Ravelo²^*, Lourenia Cassoli²^*, Mei Wu²^* and Zachary AK Frosch, MD, MSHP⁴

¹Yale School of Medicine, New Haven, CT
²Genentech, Inc., South San Francisco, CA
³Medicus Economics, Boston, MA
⁴Fox Chase Cancer Center, Philadelphia, PA

11:00 AM

783

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Carrie I Ho, MD^1,2, Neena Kennedy¹^*, Mengyang Di, MD, PhD^1,2, Ajay K. Gopal, MD^1,2, Ryan C Lynch, MD^1,2, Christina Poh, MD^1,2, Vikram Raghunathan, MD^1,2^*, Heather Rasmussen^1,2^*, Mazyar Shadman, MD, MPH^1,2, Brian G. Till, MD^1,2, Chaitra S. Ujjani, MD^1,2 and Stephen D. Smith, MD^1,2

¹Fred Hutchinson Cancer Center, Seattle, WA
²Division of Hematology and Oncology, University of Washington, Seattle, WA

11:15 AM

784

Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Jamie Johnston, MA¹^*, Katie J. Doane, MHA¹^*, Wesley Waszak²^*, Carolyn Flock³^*, Arushi Khurana, MBBS⁴, Nina Logan, MD⁵, Nanci Hawley⁶^*, Eyad Al-Hattab, M.D.⁷^*, Akeem R. Lewis, MD⁸^*, Jonathan Ticku, MD⁹^*, Amir Yosef, MD¹⁰, Stephen M. Ansell, MD, PhD¹¹, Shaji Kumar, MD¹¹, Sameer A. Parikh, MBBS¹¹, Mithun V Shah, M.D., Ph.D.¹¹, Thomas E. Witzig, MD¹² and Grzegorz S. Nowakowski, MD¹¹

¹Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN
²Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Phoenix, AZ
³Oncology/Hematology, Mayo Clinic, La Crosse, WI
⁴Internal Medicine, Mayo Clinic, Rochester, MN
⁵The Leukemia & Lymphoma Society, Atlanta, GA
⁶Research Administration, Mayo Clinic, Rochester, MN
⁷Oncology/Hematology, Mayo Clinic, Eau Claire, WI
⁸Oncology/Hematology, Mayo Clinic, Albert Lea, MN
⁹Hematology/Oncology, Mayo Clinic, La Crosse, WI
¹⁰Oncology/Hematology, Mayo Clinic, Mankato, MN
¹¹Division of Hematology, Mayo Clinic, Rochester, MN
¹²Division of Hematology, Mayo Clinic, Stabile 628, Rochester, MN

11:30 AM

785

Churn, Churn Churn! a Mixed Methods Analysis of Young Adult Leukemia and Lymphoma Survivors’ Experience Navigating the Insurance Landscape in a Post Affordable Care Act Era

Daniel J. Zheng, MD¹, Rachel Murphy-Banks, MA²^*, Angie Mae Rodday, PhD³, Qingyan Xiang, PhD³^*, Nadine Linendoll, PhD, MDiv, GNP²^*, Melissa P Beauchemin, PhD, RN, CPNP-PC⁴^*, Timothy J. D. Ohlsen, MD, MS⁵^*, Emma Fleisher, MD³^*, Kimberly A. Miller, PhD, MPH⁶^*, David R. Freyer, DO, MS⁷^*, Howland E. Crosswell, MD⁸^*, Randall Chan, MD⁹^*, Michael E. Roth, MD¹⁰ and Susan K. Parsons, MD, MRP²

¹Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
²Division of Hematology and Oncology and Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA
³Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA
⁴Division of Scholarship & Research, Columbia University School of Nursing, New York, NY
⁵Division of Pediatric Hematology and Oncology, Seattle Children’s Hospital, Seattle, WA
⁶Department of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA
⁷Departments of Pediatrics, Medicine, and Population and Public Health Sciences, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA
⁸AYA Cancer Care Program, Bon Secours Mercy, St. Francis Cancer Center, Greenville, SC
⁹Department of Pediatrics, Los Angeles General Medical Center, Los Angeles, CA
¹⁰Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

11:45 AM

786

Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer

Jalpa A. Doshi, PhD¹^*, Pengxiang Li, PhD²^*, Zhi Geng, MD, MPH²^*, Xiudong Lei, PhD³^*, Amy Pettit, PhD⁴^*, Katrina A. Armstrong, MD⁵^*, Scott F Huntington⁶ and John K Lin⁷^*

¹Division of General Medicine, Department of Medicine,Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA
²Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA
³Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Independent Consultant, Boston, MA
⁵Vagelos College of Physicians and Surgeons, Columbia University, New York, NY
⁶Yale School of Medicine, New Haven, CT
⁷MD Anderson, Houston

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

902.O1.6 902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials